Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
Date:2/27/2013
ed to adjusted earnings from operations of $363.8 million in the comparable prior year period. This increase was driven by higher gross profit in the current year, as discussed above, partially offset by increases in research and development costs ("R&D") and selling, general and administrative costs ("SG&A"). R&D increased primarily due to the expenses related to the development of the respiratory and biologics programs as well as the timing of internal and external product development projects. SG&A increased as a result of increased marketing costs in our Specialty segment, and higher employee benefit costs.
Interest expense for the three months ended December 31, 2012, totaled $74.6 million, compared to $81.1 million for the comparable prior year period. Adjusted interest expense, as further defined below, for the three months ended December 31, 2012 was $59.3 million as compared to adjusted interest expense of $68.1 million in the comparable prior year period. The decrease was the result of lower interest expense on variable rate debt instruments primarily due to the refinancing of our credit agreement in November 2011.
Other income (expense), net, was income of $2.8 million in the current quarter compared to expense of $37.4 million in the comparable prior year period. Generally included in other income (expense), net, are losses from equity affiliates, foreign exchange gains and losses and interest and dividend income. Additionally, included in the prior year period are charges associated with the termination of certain interest rate swaps totaling $13.9 million and the write-off of previously deferred financing fees of $20.1 million related to the refinancing of our senior credit facility in November 2011.
Net earnings attributable to Mylan Inc. increased $32.5 million, or 25.1%, to $162.0 million for the three months ended December 31, 2012 as compared to $129.5 million for the prior year comparable period. Adjusted ear
'/>"/>
| SOURCE Mylan Inc. Copyright©2012 PR Newswire. All rights reserved |
Related medicine technology :
1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
2. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
3. Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast
4. Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
5. Mylan Announces Pricing of Senior Notes
6. Moodys and Standard & Poors Upgrade Mylan to Investment Grade Credit Ratings
7. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
8. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
9. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
10. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
11. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
Post Your Comments:
(Date:5/24/2013)... N.C. , May 24, 2013 Regulatory ... the forefront of many organizations, priority list. ... medical device sectors understand a strong Medical ... challenges in clinical development, market education , ... to create a vital bridge between an organization ...
(Date:5/24/2013)... N.J. , May 24, 2013 BD (Becton, Dickinson ... medical technology company, announced today that it will present at ... on Thursday, May 30, 2013, at 10:40 a.m. (ET). ... accessed from the BD corporate website at www.bd.com/investors ... 2013. About BD BD is ...
(Date:5/24/2013)... Calif. , May 24, 2013 /PRNewswire-iReach/ -- Phoenix ... leading non-profit substance abuse services organization, is hosting its ... Beverly Hills Hotel on June 6, 2013. More than ... raise funds for the adolescent residential treatment centers, family ... as honor individuals whose accomplishments have positive influences on ...
Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3... Meets Primary Endpoint in,Rheumatoid Arthritis Patients Who ... -, NUTLEY, N.J., July 10, 2007 /PRNewswire/ ... Actemra Radiate (RheumAtoiD,ArthritIs Study in Anti-TNF FailurEs) ... with moderate to severe rheumatoid,arthritis (RA) who ...
... Humira Estimated to Increase the,Maximal Steady ... 100%,-, SAN DIEGO, July 09, 2007 ... biopharmaceutical company developing and,commercializing recombinant human ... the Enhanze(TM) Technology clinical trial,demonstrating improved ...
Cached Medicine Technology:Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 2Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 3Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,ArthritisHalozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society
(Date:5/24/2013)... May 24, 2013 ShopPharmacyCounter.com PhenObestin 37.5 ... ShopPharmacyCounter.com have announced price reductions on their popular PhenObestin ... which helps clients to lose weight as effortlessly as ... 37.5 by more than 50%. , Bottles have been ... time and all orders will receive free shipping. ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... Before you start the grill, before you watch ... Lee Gifford and Hoda Kotb on the Today Show on Memorial ... ideas to Kathie Lee and Hoda, including the new LawnBott® LB75 ... and women in the military who made the ultimate sacrifice for ... time with friends and family and enjoy the day. With ...
(Date:5/24/2013)... York (PRWEB) May 24, 2013 ... DePuy hip recall continue to move forward in courts ... to documents filed in California’s San Francisco Superior Court ... an expedited trial of her DePuy hip lawsuit is ... DePuy Orthopaedics, Inc., et al., No. CGC11508806; Calif. Super. ...
(Date:5/24/2013)... for heart failure appear to have better odds of ... morning, a new study finds. Death rates and ... admitted in January, on Fridays and overnight, according to ... Saturday in Portugal at the annual meeting of the ... "The fact that patients admitted right before ...
Breaking Medicine News(10 mins):Health News:ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now On 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:LawnBott® Visits the Today Show with Kathie Lee and Hoda 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2[0] ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now On[0] Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma[0] LawnBott® Visits the Today Show with Kathie Lee and Hoda[0] DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case[0] Monday Best Time for Hospitalization With Heart Failure, Study Says
... of SEIU UHW will hold a news conference at 3 p.m. ... to release newly obtained information showing that ousted union President Sal ... attorney that some of the actions may be illegal but took ... to cover them up. , , The documents detailing ...
... WAYNE, N.J., July 9 Today, Bayer HealthCare Pharmaceuticals ... designed to make infusion of recombinant factor VIII easier ... caregivers. The centerpiece of the program is an ... allows patients to practice the technique of self-injection without ...
... who had first period before age 12 are at increased risk ... Among women with ovarian cancer, those who had their first menstrual ... menstrual cycles over a lifetime are more likely to die of ... study shows. , U.S. researchers analyzed data on 410 women, aged ...
... cardiac CT for low-risk chest pain patients in the emergency ... may reduce a patients length of stay and hospital charges, ... School of Medicine, Seattle, WA. The SOC workup, which is ... tests, ECGs and nuclear stress testing. , , Fifty ...
... ... ... Drug Information Association (DIA), in collaboration with the Generic Pharmaceutical Association (GPhA), PhRMA, ... Registration--FDA and Industry: Overview and Lessons Learned on SPL (August 11-12; Philadelphia, PA) ...
... ... ... The American Academy of Orthopaedic Surgeons (AAOS) has opened the call for submissions to its ... musculoskeletal health issues and healthy behaviors in the care of bones, joints and muscles. ...
Cached Medicine News:Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 2Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 3Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 4Health News:Bayer HealthCare Launches Hemophilia Self-Infusion Training Program 5Health News:Early Menstruation Lowers Odds of Surviving Ovarian Cancer 2Health News:Early Menstruation Lowers Odds of Surviving Ovarian Cancer 3Health News:DIA Workshop Features Industry and FDA for Discussion of Best Practices for Electronic Establishment Registration and Product Listing 2Health News:Got Moving Stories? Calling All Reporters, Writers, Producers and Editors 2Health News:Got Moving Stories? Calling All Reporters, Writers, Producers and Editors 3Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up WrongdoingBayer HealthCare Launches Hemophilia Self-Infusion Training ProgramEarly Menstruation Lowers Odds of Surviving Ovarian Cancer Cardiac CT is more cost effective when managing low-risk patients with chest painDIA Workshop Features Industry and FDA for Discussion of Best Practices for Electronic Establishment Registration and Product ListingGot Moving Stories? Calling All Reporters, Writers, Producers and Editors
Phaco chopper, a combination of a modified microfinger and a pointed "quick chop" tip. For use in the left hand....
The titanium sleeve is coated with hydroxyapatite (HA) which allows vascular ingrowth, firmly secures the peg in the sphere, and enhances biocompatibility. To hold prosthetic eye. For improved occula...
... Brown nucleus cracker with straight shaft ... viscoelastic, thereby, maintains anterior chamber depth ... Accomplished with a design that keeps ... blocking outflow of viscoelastic. Available with ...
Epilation forceps straight ends size 3.5"....
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |